Business Context and Reporting Period
Company: Arvinas, Inc.
Filing Type: Form 8-K (Current Report)
Date: December 10, 2021
Subject: Regulation FD Disclosure and Other Events regarding clinical program updates for ARV-471, a PROTAC protein degrader for ER+/HER2- breast cancer.
Key Financial Metrics
This filing is a current report focused on clinical trial data and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The Company announced updated data from the dose escalation portion of its Phase 1/2 clinical trial of ARV-471 (data cut-off: September 30, 2021).
- Enrollment: 60 adult patients treated with doses ranging from 30 mg to 700 mg. The cohort was heavily pretreated (median of four prior therapies), with 100% prior CDK 4/6 inhibitor exposure, 80% prior fulvestrant, and 78% prior chemotherapy.
- Efficacy: Among 47 evaluable patients, the clinical benefit rate was 40%. Three confirmed partial responses were observed. Two patients remained on treatment for over 18 months.
- Safety: No maximum tolerated dose was reached. No dose-limiting toxicities or Grade 4 treatment-related adverse events (TRAEs) were observed. Common TRAEs included nausea (29%), fatigue (20%), and vomiting (10%). Four patients experienced six Grade 3 TRAEs; only one patient discontinued due to a TRAE (venous embolism).
- ER Degradation: Robust estrogen receptor (ER) degradation up to 89% was observed in paired biopsies from 14 patients, regardless of ESR1 mutation status.
- Pharmacokinetics: Dose-related increase in plasma exposure observed; mean exposure on day 15 exceeded nonclinical efficacious ranges at doses ≥ 60 mg daily.
Guidance, Outlook, and Risks
Future Plans (2022):
- Initiate Phase 3 studies for metastatic breast cancer (monotherapy and combination).
- Initiate two additional trials: a Phase 1b combination trial with everolimus and a Phase 2 neoadjuvant trial in early breast cancer.
- Present data from the ongoing Phase 1b combination study with IBRANCE (palbociclib) and the Phase 2 monotherapy dose expansion study.
Risks and Contingencies:
- Forward-looking statements regarding clinical development, regulatory status, and commercialization involve substantial risks and uncertainties.
- Actual results may differ materially from expectations due to factors including the ability to successfully conduct trials and receive results on expected timelines.
- The Company assumes no obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and presentation (Exhibit 99.2) for detailed statistical tables not summarized in the 8-K text.
- Confirm the specific timelines for the initiation of Phase 3 studies in 2022.
- Review the "Risk Factors" section in the Company's most recent 10-K or 10-Q for a comprehensive list of risks affecting clinical development.
- Monitor subsequent filings for updates on the Phase 1b combination study with palbociclib and the Phase 2 dose expansion study.